Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelofibrosis Due to and Following Polycythemia Vera”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03441113
What this trial is testing

Extended Access of Momelotinib in Adults With Myelofibrosis

Who this might be right for
NeoplasmsPost-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)+2 more
GlaxoSmithKline 237
Large-scale testing (Phase 3)Looking for participantsNCT06351631
What this trial is testing

Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Who this might be right for
Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosis+3 more
Merck Sharp & Dohme LLC 400
Large-scale testing (Phase 3)Ended earlyNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Testing effectiveness (Phase 2)Study completedNCT04676529
What this trial is testing

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Who this might be right for
MyelofibrosisPrimary Myelofibrosis (PMF)Post- Essential Thrombocythemia Myelofibrosis+1 more
Syntara 43
Large-scale testing (Phase 3)Study completedNCT01178281
What this trial is testing

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Who this might be right for
Primary MyelofibrosisMPN-associated Myelofibrosis
Celgene 267
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Ended earlyNCT01790295
What this trial is testing

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost Polycythemia Vera MyelofibrosisPost Essential Thrombocythemia Myelofibrosis
John Mascarenhas 21
Early research (Phase 1)Looking for participantsNCT07379125
What this trial is testing

Therapeutic RSK1 Targeting in Myelofibrosis

Who this might be right for
Myelofibrosis
Washington University School of Medicine 18
Large-scale testing (Phase 3)Study completedNCT00952289
What this trial is testing

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 309
Large-scale testing (Phase 3)Looking for participantsNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Early research (Phase 1)Ended earlyNCT01730248
What this trial is testing

Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Looking for participantsNCT05280509
What this trial is testing

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT01633372
What this trial is testing

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 87
Early research (Phase 1)Looking for participantsNCT06218628
What this trial is testing

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Fox Chase Cancer Center 24
Large-scale testing (Phase 3)Ended earlyNCT02055781
What this trial is testing

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
CTI BioPharma 311
Testing effectiveness (Phase 2)Study completedNCT02966353
What this trial is testing

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Study completedNCT00935987
What this trial is testing

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 166
Testing effectiveness (Phase 2)Ended earlyNCT01523171
What this trial is testing

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 97
Testing effectiveness (Phase 2)Looking for participantsNCT06327100
What this trial is testing

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT01348490
What this trial is testing

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 66
Next Page